GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Resonance Health Ltd (ASX:RHT) » Definitions » Debt-to-EBITDA

Resonance Health (ASX:RHT) Debt-to-EBITDA : -0.34 (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Resonance Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Resonance Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.13 Mil. Resonance Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.19 Mil. Resonance Health's annualized EBITDA for the quarter that ended in Dec. 2023 was A$-0.94 Mil. Resonance Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.34.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Resonance Health's Debt-to-EBITDA or its related term are showing as below:

ASX:RHT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.32   Med: -0.17   Max: 0.11
Current: -0.32

During the past 13 years, the highest Debt-to-EBITDA Ratio of Resonance Health was 0.11. The lowest was -0.32. And the median was -0.17.

ASX:RHT's Debt-to-EBITDA is ranked worse than
100% of 423 companies
in the Healthcare Providers & Services industry
Industry Median: 2.61 vs ASX:RHT: -0.32

Resonance Health Debt-to-EBITDA Historical Data

The historical data trend for Resonance Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resonance Health Debt-to-EBITDA Chart

Resonance Health Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.14 0.11 -0.20 -0.23

Resonance Health Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.16 -0.25 -0.25 -0.34

Competitive Comparison of Resonance Health's Debt-to-EBITDA

For the Health Information Services subindustry, Resonance Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resonance Health's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Resonance Health's Debt-to-EBITDA falls into.



Resonance Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Resonance Health's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.1 + 0.173) / -1.188
=-0.23

Resonance Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.127 + 0.194) / -0.94
=-0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Resonance Health  (ASX:RHT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Resonance Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Resonance Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Resonance Health (ASX:RHT) Business Description

Traded in Other Exchanges
N/A
Address
141 Burswood Road, Level 1, Burswood, WA, AUS, 6100
Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, and HepaFat-Scan. The company's operating segment includes Services; Research and Development and Corporate. It generates maximum revenue from the Services segment. Geographically, it derives a majority of its revenue from North America and Europe-Middle-East-Africa (EMEA) and also has a presence in Asia/Pacific.

Resonance Health (ASX:RHT) Headlines

No Headlines